Consolidated sales fell 10.4% to €984 million in the three months ended March 31, 2026. On an organic basis, stripping out ...

Shares of bioMerieux were lower after the company reported a drop in its first-quarter sales and cut its full-year guidance, blaming a soft market environment.

bioMérieux (EPA:BIM) shares have continued recent momentum with a 30% gain in the last month alone. The full year gain of 40% is pretty reasonable, too. All else being equal, a sharp share price ...

On July 6, 2023, bioMérieux filed a notice of data breach with the Attorney General of Maine after discovering that a file transfer software used by a vendor contained a vulnerability allowing hackers ...

MARCY L'ÉTOILE, France and SHERBROOKE, QC, Jan. 15, 2024 /CNW/ - bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of LUMED, a software company that has ...

MARCY-L'ÉTOILE, France, Feb. 18, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of SMARTBIOME™, an innovative solution designed to ...

- Co-development of Assays and Co-distribution of a Fully Integrated Molecular Platform due for Launch in 2012 - bioMerieux Gains Exclusive Rights in Microbiology - bioMerieux Takes Equity Stake in ...

PARIS, Sept 4 (Reuters) - French biotech firm BioMerieux will buy privately-owned U.S. rival BioFire Diagnostics for $450 million, in a deal aimed at consolidating its position as a major player in ...